循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅱ章　がん医療の進歩と腫瘍循環器学

アントラサイクリン系の薬物療法とがん治療関連心機能障害（CTRCD）

著者： 赤澤宏¹

所属機関： ¹東京大学大学院医学系研究科循環器内科学

ページ範囲：P.550 - P.555

Point
・アントラサイクリン系抗がん剤による心毒性は蓄積性で用量依存性がある．
・高齢者，小児，基礎心疾患の合併，心血管リスク（喫煙，高血圧，糖尿病，脂質異常症，肥満）の合併も心毒性の危険因子となる．
・心機能低下を検出したら迅速に心保護薬（β遮断薬やレニン・アンジオテンシン系阻害薬）による治療を開始する．

参考文献

1) Ewer MS, Lippman SM:Type Ⅱ chemotherapy-related cardiac dysfunction:time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005

2) Tewey KM, Rowe TC, Yang L, et al:Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468, 1984

3) Di Marco A, Silvestrini R, Di Marco S, et al:Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells. J Cell Biol 27:545-550, 1965

4) Yang F, Teves SS, Kemp CJ, et al:Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845:84-89, 2014

5) Feinstein E, Canaani E, Weiner LM:Dependence of nucleic acid degradation on in situ free-radical production by adriamycin. Biochemistry 32:13156-13161, 1993

6) Lefrak EA, Pitha J, Rosenheim S, et al:A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973

7) Steinberg JS, Cohen AJ, Wasserman AG, et al:Acute arrhythmogenicity of doxorubicin administration. Cancer 60:1213-1218, 1987

8) Von Hoff DD, Layard MW, Basa P, et al:Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979

9) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al;ESC Scientific Document Group:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology（ESC）. Eur Heart J 37:2768-2801, 2016

10) Slamon DJ, Leyland-Jones B, Shak S, et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001

11) Schwartz RG, McKenzie WB, Alexander J, et al:Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987

12) Cardinale D, Colombo A, Bacchiani G, et al:Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015

13) Keizer HG, Pinedo HM, Schuurhuis GJ, et al:Doxorubicin（adriamycin）:a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47:219-231, 1990

14) Ichikawa Y, Ghanefar M, Bayeva M, et al:Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124:617-630, 2014

15) Capranico G, Tinelli S, Austin CA, et al:Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1132:43-48, 1992

16) Vejpongsa P, Yeh ET:Topoisomerase 2beta:a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther 95:45-52, 2014

17) Zhang S, Liu X, Bawa-Khalfe T, et al:Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639-1642, 2012

18) Renu K, V GA, P BT, et al:Molecular mechanism of doxorubicin-induced cardiomyopathy-An update. Eur J Pharmacol 818:241-253, 2018

19) Duan S, Bleibel WK, Huang RS, et al:Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 67:5425-5433, 2007

20) Visscher H, Ross CJ, Rassekh SR, et al:Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30:1422-1428, 2012

21) Aminkeng F, Bhavsar AP, Visscher H, et al:A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 47:1079-1084, 2015

22) Burridge PW, Li YF, Matsa E, et al:Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22:547-556, 2016

23) Curigliano G, Lenihan D, Fradley M, et al:Management of cardiac disease in cancer patients throughout oncological treatment:ESMO consensus recommendations. Ann Oncol 31:171-190, 2020